Fate Therapeutics’ (NASDAQ:FATE) multipronged CAR NK approach could address gaps left by single-target CAR-T therapies in B cell malignancies and chronic lymphocytic leukemia (CLL), experts said. This multiantigen targeted approach could limit antigen escape, which has been implicated in disease relapse, they added.
Manasi Vaidya joined as a reporter in New York in February 2015 and has covered the drug development space across a number of therapeutic areas, and built an expertise in writing about oncology. While focusing on analysis pieces about ongoing clinical trials, her coverage has also branched out to regulatory issues, pricing and reimbursement and patent litigation. She has covered practice-changing developments from high profile conferences like ASCO and SABC, in addition to FDA regulatory meetings. She previously covered the Asian biotechnology industry for BioSpectrum, a monthly magazine in India, for two years. She has a Masters degree in Science, Health and Environmental Reporting from New York University, and a Masters degree in Biotechnology from Dr. D. Y. Patil University. Her work has appeared in Nature Medicine, Nautilus and Technology Review India.